Clinical Study

Intrathecal Administration of Autologous CD34 Positive Cells in Patients with Past Cerebral Infarction: A Safety Study

Liming Wang, Haijie Ji, Ming Li, Jianjun Zhou, Wen Bai, Zhanqiang Zhong, Na Li, Delin Zhu, Zijia Zhang, Yongjun Liu, and Mingyuan Wu

1 Cell Therapy Center, 323 Hospital of Chinese People’s Liberation Army, Xi’an 710054, China
2 Alliancells Institute of Stem Cells and Translational Regenerative Medicine & Alliancells Bioscience Co., Ltd., Tianjin 300381, China
3 Zhongyuan Union Stem Cell Bioengineering Co., Ltd., Tianjin 300050, China
4 Beijing Alliancells-PuRui Bioscience Co., Ltd., Beijing 100052, China
5 Department of Cell Biology, Oklahoma State University, Tulsa, OK 74106, USA
6 Harold Hamm Diabetes Center and Section of Endocrinology and Diabetes in the Department of Internal Medicine, Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA

Correspondence should be addressed to Yongjun Liu; yongjunliu8959@yahoo.com.cn and Mingyuan Wu; mingyuan-wu@ouhsc.edu

Received 8 July 2013; Accepted 27 August 2013

Academic Editors: J. Chen and K. R. Pennypacker

Copyright © 2013 Liming Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Regenerative strategies in treatment of stroke have great potential. The goal of the current study was to investigate safety of intrathecal administration of autologous CD34 positive cells in treatment of patients with poststroke. A total of eight male patients with a history of stroke were enrolled. The patients were treated subcutaneously with 5 µg/kg body weight rhG-CSF for 5 consecutive days, and then leukapheresis was performed to concentrate cells for CD34 positive immunoselection. All patients underwent intrathecal administration of CD34 positive cells via lumbar puncture. The primary outcome was safety evaluation for 12-month followup. In addition, behavioral function was evaluated with NIH stroke scale and Barthel index 1, 6, and 12 months after the last treatment, respectively. There were no major adverse events, and abnormal changes of blood tests during the whole treatment process included intrathecal administration and 12-month followup. The main message from the current study was that administration of G-CSF-mobilized autologous CD34 positive cells in patients with poststroke was safe. Future studies with larger population and control group are needed to confirm the safety and investigate the efficacy.

1. Introduction

Cerebrovascular disorder, mainly including ischemic and hemorrhagic stroke, is the third cause of death after cardiovascular disease and cancer [1] and the leading cause of long-term disability in adults in China [2]. Although stroke mortality has declined in the past decades, its prevalence and morbidity increased dramatically because of enhanced stroke survival [3]. About 40% of stroke survivors have certain degree of impairment and 15–30% are severely disabled [4]. Therefore, every effort to prevent and treat stroke is urgently warranted.

Up to date, many targets within the cascade of neuronal death have been identified. However, neuroprotective strategies in treating poststroke with sequela are controversial [5]. Since neural progenitor and stem cells were discovered in the adult brain for the first time in 1992 [6], different experimental stroke models indicated that neural progenitor and stem cells with activities of migration and differentiation are activated by hypoxia in brain [7, 8]. Increasing evidence from basic studies indicates that cord blood mononuclear cells, bone marrow mononuclear cells, and bone marrow stromal cells can survive in posts ischemia tissue and reduce neuronal damage when transplanted into rodents subjected to cerebral infarction [9–12].

Bone marrow-derived CD34 positive cells have previously been used to reconstitute the hematopoietic system after radiation or chemotherapy. Recently, CD34 positive cells
Table 1: Inclusion and exclusion criteria.

| Inclusion criteria                                      | Exclusion criteria                                                                 |
|---------------------------------------------------------|-------------------------------------------------------------------------------------|
| Age ≥18 years to ≤60 years                              | Systemic malignancy                                                                 |
| Patient must comprehend the study protocol              | Hematological system disorder (e.g., myeloproliferative disorder)                   |
| Patient must be compliant                               | Thrombocyte function disorders                                                     |
| Patient provided written informed consent               | Metabolic syndrome with inadequate treatment parameters, for instance, excessive    |
|                                                         | hypertension, hyperlipemia, and hyperglycemia                                       |
|                                                         | Known deficit in hemostasis                                                        |
|                                                         | Serious coronary heart disease                                                     |
|                                                         | Sickle cell anemia                                                                 |
|                                                         | Allergy against G-CSF                                                               |
|                                                         | Pregnancy                                                                          |
|                                                         | Any other serious disease, for instance, severe psychiatric disorder (major depression, |
|                                                         | schizophrenic psychosis, and addiction), severe cardiac disorder with hemodynamic   |
|                                                         | relevance and positive HIV serology                                                |
|                                                         | Epilepsy                                                                           |
|                                                         | Hydrocephaly                                                                       |

have been widely reported to induce therapeutic angiogenesis in animal models of myocardial, peripheral, and cerebral ischemia [13–15]. Circulating bone marrow-derived immature cells, including CD34 positive cells, have been implicated in homeostasis of the cerebral microvasculature [16]. In addition, the level of circulating CD34 positive cells was decreased in patients with vascular-type cognitive impairment [17]. Recently, the positive correlation between the number of circulating CD34 positive cells and patients with acute stroke stress has been demonstrated, which suggests that increased numbers of circulating CD34 positive cells might benefit neurologic function recovery [18]. Although previous clinical data have demonstrated a positive benefit in patients with stroke [19], there are no clinical reports on autologous CD34 positive precursor cells in the treatment of poststroke.

In our ongoing clinical study, we designed a protocol to determine the safety and potential efficacy of G-CSF mobilization of bone marrow-derived CD34 positive cells in the treatment of patients with a history of stroke. In the current study, we focused on the investigation of the safety of CD34 positive cell administration.

2. Material and Methods

2.1. Clinical Study Design. This was a prospective and observational study. The study was approved by the Institutional Review Boards of 323 Hospital of PLA (Xi’an, China). The study was conducted according to the principles of the Declaration of Helsinki. All study participants provided written informed consent. The procedure of our ongoing clinical study was under STEPS criteria [20, 21].

2.2. Patients. Eight male patients with a history of stroke and left sequela were the target population in this study. The inclusion and exclusion criteria are listed in detail in Table 1.

2.3. G-CSF, CD34 Positive Cell Harvesting and Immunoselection. All patients were treated subcutaneously with 5 μg/kg body weight G-CSF for five consecutive days. Leukapheresis was performed using a Cobe Spectra cell separator (Cobe Bct, Lakewood, CO). Blood pressure and heart rate were monitored, and a physician was available for any emergencies during the performance. CD34 positive cells were extracted from leukapheresis products by immunoselection using an automated cell separation system (Miltenyi Biotec, Bergisch Gladbach, Germany) based on the mechanism of selectivity of a monoclonal CD34 antibody conjugated to a magnetic particle [22, 23]. For purity analysis of immunoselected CD34 positive cells, cells were evaluated by flow cytometry using CD34-PE-conjugated monoclonal antibody. Then the immunoselected CD34 positive cell components were divided into multiunits stored in liquid phase nitrogen at −196°C and will be infused later. The purity of CD34 positive cells was in the range of 85–90%. 0.8–3.3 × 10^7 (varying from different patients) in 2 mL medium was used per time. The cells from the Good Manufacturing Practice (GMP) workshop were ensured to have been fully screened against potential pathogens and meet the eligible criteria for clinical use.

2.4. Cell Administration. All subjects were hospitalized during the administration of CD34 positive cells. Patients’ X-rays, computed tomography scans, and magnetic resonance images of spine were reviewed prior to administration. Intrathecal injection by lumbar puncture was repeated four or five times depending on the patient’s condition. Treatments were separated by one-week interval. Patients were given local anesthesia, and lumbar puncture was performed in the lateral decubitus position, prepped, and draped in sterile fashion, and the needle was placed in the lumbar cistern. 2 mL of cerebrospinal fluid was removed and replaced by 2 mL of immunoselected CD34 positive cell suspension.
6th, and 12th month in the 12-month followup. Functional disability, were documented at baseline and at 1st, 2.5. Safety Evaluation and Followup. Clinical chemistry monitoring, including tests of blood count, liver function, renal function, lipids, and glucose, was performed before, 1 day, and 7 days after cell treatment, respectively. The treatment patients were also under rehabilitation training and followed up for 12 months. Any adverse events that occurred in the treatment were documented. In addition, NIH stroke scale and Barthel index, which are widely used in evaluation of functional disability, were documented at baseline and at 1st, 6th, and 12th months in the 12-month followup.

2.6. Statistical Analysis. Parameters measured before and after treatment were compared using a Student’s t-test. A P value of < 0.05 was considered significant.

3. Results

3.1. Basic Information. As shown in Table 2, 8 male patients (age: 22–58 yrs, median: 42 yrs) with a history of stroke (range: 1–7 yrs, median: 2 yrs) were enrolled. G-CSF and leukapheresis were well tolerated in all patients during the clinical treatment course. A mean of 1.8 × 10^7 of CD34 positive cells (range 0.8–3.3) was collected by immunoselection. Flow cytometry analysis showed that CD34 positive cells in the immunoselected fraction were above 85%. The patients received four or five times cell transplantation during the whole course.

3.2. Safety Evaluation. No allergic or immunological reactions were noted at the time of injection or while under observation. No chest pain and abnormal level of cardiac enzymes were observed. In addition, there is no statistical difference of blood tests (Tables 3 and 4) before treatment, 1 day, and 7 days after treatment. Therefore, the above data indicated that cell infusion into the subarachnoid space was a safe procedure in patients with poststroke.

3.3. Efficacy Evaluation. As shown in Table 5, we observed that the daily activities had a gradual improvement tendency in the 12-month followup. Mean of NIH stroke scale and BI scores shifted from 7.5 and 43.8 at baseline to 4.4 and 64.4 in 12 months later, respectively. There was no significant difference one month after the treatment compared to baseline. Improvement was observed 6 and 12 months after the last treatment. The improvements of muscle tone, rigidity, and motor power were observed in all patients. However, we must emphasize that patients with stroke do gradually improve their functions, and here it is not possible to define whether the therapy itself or the natural history of the disease is responsible for the improvements noted.

4. Discussion

In the current study, we observed that G-CSF administration, leukapheresis, and intrathecal administration of CD34 positive cells were safe and well tolerated in a group of

| Patient | Gender | Age (yrs) | Stroke age (yrs) | CD34 positive cells (×10^7) | Number of times |
|---------|--------|-----------|-----------------|----------------------------|----------------|
| 1       | Male   | 58        | 4               | 1                          | 4              |
| 2       | Male   | 43        | 7               | 0.8                        | 4              |
| 3       | Male   | 41        | 1               | 2.7                        | 5              |
| 4       | Male   | 44        | 3               | 1.4                        | 4              |
| 5       | Male   | 22        | 1               | 1.2                        | 4              |
| 6       | Male   | 40        | 2               | 3.3                        | 4              |
| 7       | Male   | 47        | 2               | 0.9                        | 4              |
| 8       | Male   | 37        | 1               | 3.1                        | 5              |

Table 2: The basic information of eight patients.

| Time points | RBC (×10^12/L) | WBC (×10^9/L) | PLT (×10^9/L) | HB (g/L) |
|-------------|---------------|---------------|---------------|----------|
| Baseline    | 4.7 ± 0.6     | 8.9 ± 1.3     | 204.4 ± 89.0  | 127.5 ± 11.6 |
| 1 day       | 3.9 ± 0.4     | 7.5 ± 1.6     | 217.1 ± 70.8  | 122.6 ± 17.3 |
| 7 day       | 4.1 ± 0.8     | 7.9 ± 1.8     | 207.3 ± 97.8  | 121.7 ± 16.1 |

Table 3: Changes of RBC, WBC, PLT, and HB in blood before and after treatment (n = 8, mean ± SD).

| Item (unit) | Baseline | 1 day | 7 day |
|------------|----------|-------|-------|
| TP (g/L)   | 64.4 ± 6.1 | 66.4 ± 5.9 | 65.3 ± 5.6 |
| ALB (g/L)  | 39.4 ± 4.6   | 41.4 ± 3.8  | 41.1 ± 3.7  |
| GLB (g/L)  | 25.6 ± 4.5    | 26.4 ± 4.9   | 24.3 ± 5.0  |
| TBIL (μmol/L) | 7.8 ± 1.4    | 8.6 ± 1.1    | 6.9 ± 2.8   |
| DBIL (μmol/L) | 3.1 ± 0.8    | 3.3 ± 0.6    | 2.7 ± 1.0   |
| ALT (μmol/L)   | 25.2 ± 6.9    | 37.2 ± 4.5    | 27.3 ± 13.4  |
| AST (μmol/L)   | 17.5 ± 3.3    | 27.9 ± 5.2    | 21.8 ± 4.9   |
| UA (μmol/L)   | 240.7 ± 38.5  | 256.9 ± 71.5  | 239.5 ± 53.9 |
| Cr (μmol/L)   | 50.5 ± 12.1   | 48.6 ± 11.5   | 45.6 ± 11.2  |
| BUN (mmol/L)  | 5.3 ± 1.4     | 5.6 ± 1.7     | 4.1 ± 2.1    |
| CHOL (mmol/L) | 4.5 ± 0.61    | 4.3 ± 0.90    | 4.1 ± 0.88   |
| TG (mmol/L)   | 1.1 ± 0.37    | 1.3 ± 0.46    | 1.2 ± 0.82   |
| GLU (mmol/L)  | 4.8 ± 0.74    | 5.1 ± 0.38    | 4.9 ± 0.58   |

Table 4: The blood biochemical analysis before and after treatment (n = 8, mean ± SD).

TP: total protein; ALB: albumin; GLB: globulin; TBIL: total bilirubin; DBIL: direct bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; UA: uric acid; Cr: creatinine; BUN: blood urea nitrogen; CHOL: cholesterol; TG: triglyceride; GLU: glucose.

Table 5: The changes of RBC, WBC, PLT, and HB in blood before and after treatment (n = 8, mean ± SD).
Table 5: The comparison of NIHSS score and BI score before and followed up for 1, 6, and 12 months after the last cell transplantation.

| Patient | NIHSS score | Baseline | 1 | 6 | 12 | Baseline | 1 | 6 | 12 |
|---------|-------------|----------|---|---|----|----------|---|---|----|
| 1       | 8           | 8        | 7 | 6 | 35 | 35       | 40| 65|    |
| 2       | 3           | 3        | 2 | 1 | 40 | 45       | 55| 80|    |
| 3       | 17          | 16       | 11| 7 | 0  | 0        | 10| 25|    |
| 4       | 3           | 3        | 2 | 1 | 2  | 65       | 65| 65| 80 |
| 5       | 4           | 4        | 3 | 1 | 70 | 70       | 75| 80|    |
| 6       | 3           | 3        | 3 | 2 | 70 | 70       | 70| 80|    |
| 7       | 2           | 2        | 1 | 0 | 70 | 70       | 80| 95|    |
| 8       | 20          | 20       | 17| 16|    | 0        | 5 | 5 | 10 |
| Mean    | 7.5         | 7.4      | 5.9| 4.4| 43.8| 45       | 50| 64.4|    |
| P value | —           | >0.05    | >0.05| <0.05| —     | >0.05    | <0.05| <0.01|    |

The NIHSS score and BI score of 1, 6, and 12 month were compared to the corresponding baseline, respectively.

patients with past cerebral infarction with 12-month followup.

G-CSF has been used extensively in the last decades to mobilize CD34 positive hematopoietic stem cells in neutropenic patients and for reconstitution of bone marrow [24, 25]. Recently, G-CSF as a promising drug candidate can reduce neuroinflammation and potentiate both neurogenesis and angiogenesis after ischemic stroke by promoting bone marrow cell migration into the ischemic brain [26, 27]. Many years of clinical experience with G-CSF have shown the safety of this agent in the general population [28]. Increasing clinical studies indicated mobilization of CD34 positive precursor cells in patients with acute stroke by G-CSF is safe and effective [29–31]. In the current study, patients with past cerebral infarction were treated by G-CSF; subsequently, leukapheresis was performed for CD34 positive cells collection by immunoselection. There were no emergencies, and adverse events, such as hyperviscosity syndromes, occurred in the whole process.

Previously, it has been reported that intrathecal administration was safe with a variety of stem cells including adipose tissue-derived mesenchymal stem cells, embryonic stem cell-derived hematopoietic stem cells, and autologous bone marrow-derived hematopoietic stem cells in the treatment of neurological disorders [32, 33]. In this study, intrathecal injection of the CD34 positive cells into subarachnoid space was performed, thereby migrating more efficiently into the injured area related to stroke through cerebrospinal fluid compared to the intravenous route. What is more, there were no side effects including headache, low-grade fever, and meningism and vomiting occurring in eight patients.

CD34 positive cells comprise a population enriched with endothelial progenitor cells whose contribution to neovascularization includes both direct participation in forming the neovessel and regulatory roles and the sources of growth/angiogenesis factors including VEGF, HGF, and IGF-I [34], contributing to the maintenance of the microvasculature. The positive correlation between levels of circulating CD34 positive cells and neovascularization in patients with postcerebral ischemia was observed [35]. In this study, given the variance of age, transplantation cell numbers, and stroke history, the discrepant response to the treatment is apprehensible. The current data showed a trend that CD34 positive cells might achieve clinical benefits in the treatment of patients with poststroke. However, improvements do occur naturally in patients with stroke, and it is not possible to define whether the therapy itself or the natural history of the disease was responsible for the improvements noted.

In conclusion, this study indicates that intrathecal administration of CD34 positive cells in patients with past stroke is a relatively safe and simple procedure with no long-term adverse effects. However, further larger clinical studies with multiple groups including blinding and placebo controls will be required to confirm our findings in the current study.

Conflict of Interests

The authors indicate no potential conflict of interests.

Authors’ Contribution

Liming Wang and Haijie Ji have contributed equally to this work.

Acknowledgments

This study was supported by the Shaanxi Province Social Development Public Relations Project (2012K13-02-35), the Key Sciences and Technology Project in Hainan Province (ZDZX2013003-2), and the Military Medicine and Public Health Plan (CLZ120GA23).

References

[1] J. He, D. Gu, X. Wu et al., “Major causes of death among men and women in China,” The New England Journal of Medicine, vol. 353, no. 11, pp. 1124–1134, 2005.
[2] R. Bonita, S. Mendis, T. Truelsen, J. Bogousslavsky, J. Toole, and F. Yatsu, “The global stroke initiative,” Lancet Neurology, vol. 3, no. 7, pp. 391–393, 2004.
[3] B. Jiang, W.–Z. Wang, H. L. Chen et al., “Incidence and trends of stroke and its subtypes in China: results from three large cities,” Stroke, vol. 37, no. 1, pp. 63–68, 2006.
[4] B. Bates, J. Y. Choi, P. W. Duncan et al., "Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care: executive summary," Stroke, vol. 36, no. 9, pp. 2049–2056, 2005.

[5] M. Fisher, G. Feuerstein, D. W. Howells et al., "Update of the stroke therapy academic industry roundtable preclinical recommendations," Stroke, vol. 40, no. 6, pp. 2244–2250, 2009.

[6] B. A. Reynolds and S. Weiss, "Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system," Science, vol. 255, no. 5052, pp. 1707–1710, 1992.

[7] T. Masuda, Y. Isobe, N. Aihara et al., "Increase in neurogenesis and neuroblast migration after a small intracerebral hemorrhage in rats," Neuroscience Letters, vol. 425, no. 2, pp. 114–119, 2007.

[8] R. Zhang, Z. Zhang, C. Zhang et al., "Stroke transiently increases subventricular zone cell division from asymmetric to symmetric and increases neuronal differentiation in the adult rat," Journal of Neuroscience Research, vol. 24, no. 5, pp. 5810–5815, 2004.

[9] M. Brenneman, S. Sharma, M. Harting et al., "Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats," Journal of Cerebral Blood Flow and Metabolism, vol. 30, no. 1, pp. 140–149, 2010.

[10] M. Hokari, S. Kuroda, H. Shichinohe, S. Yano, K. Hida, and A. Taguchi, T. Soma, H. Tanaka et al., "Administration of CD34+ stem cells: In vivo differentiation of human CD34+ hematopoietic cells, colony-forming cells and colony stimulating factor-mobilized CD34 positive cells in patients with critical limb ischemia," Atherosclerosis, vol. 224, pp. 440–445, 2012.

[11] S. H. Chen, F. M. Bath, L. Zhao et al., "Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors," Blood, vol. 68, no. 1, pp. 162–166, 1986.

[12] D. J. Prockop, C. A. Gregory, and J. L. Spees, "One strategy for cell and gene therapy: Harnessing the power of adult stem cells to repair tissues," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, supplement 1, pp. 11917–11923, 2003.

[13] F. Benedetti, "The CD34+ cell: biological aspects," Tumori, vol. 82, no. 2, pp. S3–S13, 1996.

[14] A. Taguchi, T. Soma, H. Tanaka et al., "Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model," The Journal of Clinical Investigation, vol. 114, no. 3, pp. 330–338, 2004.

[15] W.-C. Shyu, S.-Z. Lin, M.-F. Chiang, C.-Y. Su, and H. Li, "Intracerebral peripheral blood stem cell (CD34+) implantation induces neuroplasticity by enhancing β1 integrin-mediated angiogenesis in chronic stroke rats," Journal of Neuroscience, vol. 26, no. 13, pp. 3444–3453, 2006.

[16] A. Taguchi, "Cell-based therapy for patients with vascular dementia," Psychogeriatrics, vol. 11, no. 2, pp. 113–115, 2011.

[17] A. Taguchi, T. Matsuyma, T. Nakamori et al., "Circulating CD34-positive cells provide a marker of vascular risk associated with cognitive impairment," Journal of Cerebral Blood Flow and Metabolism, vol. 28, no. 3, pp. 445–449, 2008.

[18] A. Taguchi, T. Matsuyma, H. Moriwaki et al., "Circulating CD34-positive cells provide an index of cerebrovascular function," Circulation, vol. 109, no. 24, pp. 2972–2975, 2004.

[19] A. R. Mackie and D. W. Losordo, "CD34-positive stem cells: in the treatment of Heart and vascular disease in human beings," Texas Heart Institute Journal, vol. 38, no. 5, pp. 474–485, 2011.
long-term culture initiating cells into the peripheral blood of patients with an acute cerebral ischemic insult,” *Cytotherapy*, vol. 10, no. 3, pp. 303–311, 2008.

[35] M. Majka, A. Janowska-Wieczorek, J. Ratajczak et al., “Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner,” *Blood*, vol. 97, no. 10, pp. 3075–3085, 2001.